The Royal Marsden Hospital - Drug Development Unit
Welcome,         Profile    Billing    Logout  
 8 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lopez, Juanita
IMC-C103C-101, NCT03973333: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Withdrawn
1/2
75
Europe, US
IMC-C103C, Atezolizumab, TECENTRIQ
Immunocore Ltd
Select Advanced Solid Tumors
09/23
09/23
IceCAP, NCT03673787: A Trial of Ipatasertib in Combination With Atezolizumab

Recruiting
1/2
87
Europe
ipatasertib, Atezolizumab
Institute of Cancer Research, United Kingdom, Hoffmann-La Roche
Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
11/23
11/23
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Hourglass Oct 2024 - Dec 2024 : Data for late-line NSCLC
Recruiting
1/2
727
Europe, Canada, US, RoW
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
02/26
08/26
AFM24-102, NCT05109442 / 2021-000707-20: Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH, Affimed GmbH
Advanced Solid Tumor
02/25
11/25
5G-RUBY, NCT06630260: Avutometinib and Defactinib in Malignant Brain Tumours

Recruiting
1/2
182
Europe
Avutometinib, VS-6766, Defactinib, Temozolomide, Temodal
Institute of Cancer Research, United Kingdom, Minderoo Foundation, Verastem, Inc., Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Cancer Research UK, University of Cambridge
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
09/29
09/30
Keynote-D20, NCT04752826 / 2020-002090-10: BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies

Recruiting
1/2
100
Europe, US, RoW
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
BioInvent International AB, Merck Sharp & Dohme LLC
Advanced Malignancies
12/26
01/28
BT7480-100, NCT05163041: Study in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Recruiting
1/2
200
Europe, US
BT7480, Nivolumab
BicycleTx Limited
Advanced Solid Tumor
09/25
12/25
NCT03447470 / 2017-000720-98: Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Completed
1
46
Europe
RXC004, Nivolumab
Redx Pharma Ltd
Cancer, Solid Tumor
09/23
09/23
NVG111-101, NCT04763083 / 2020-000820-20: First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Recruiting
1
90
Europe
NVG-111
NovalGen Ltd.
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non-small Cell Lung Cancer (NSCLC), Malignant Melanoma
12/23
12/25
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
5G-EMERALD, NCT06632236: Amivantamab in Malignant Brain Tumours

Recruiting
1
12
Europe
Amivantamab, JNJ-61186372
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Janssen Pharmaceutica N.V., Belgium, Cancer Research UK, Minderoo Foundation, University of Cambridge
Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
03/26
03/27
ASTEROID, NCT05082259: A Trial of ASTX660 in Combination With Pembrolizumab

Recruiting
1
48
Europe
ASTX660, Tolinapant, Pembrolizumab, MK-3475
Institute of Cancer Research, United Kingdom, Astex Pharmaceuticals, Inc., Merck Sharp & Dohme LLC, Cancer Research UK
Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer
03/26
03/26
CONSENT, NCT04407676: Improving Informed Consent for Early Phase Anti-Cancer Trials

Recruiting
N/A
34
Europe
Summary PIS and Online Video Modules
Royal Marsden NHS Foundation Trust
Solid Neoplasms
11/22
03/23

Download Options